Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit.

Kim, LG; Caplin, B; Cleary, F; Hull, SA; Griffith, K; Wheeler, DC; Nitsch, D; UK National Chronic Kidney Disease Audit

This is a pre-copyedited, author-produced version of an article accepted for publication in Nephrology Dialysis Transplantation, following peer review. The version of record: Lois G. Kim, Ben Caplin, Faye Cleary, Sally A. Hull, Kathryn Griffith, David C. Wheeler, Dorothea Nitsch, on behalf of the UK National Chronic Kidney Disease Audit; Accounting for overdispersion when determining primary care outliers for the identification of chronic kidney disease: learning from the National Chronic Kidney Disease Audit, Nephrology Dialysis Transplantation, Volume 32, Issue suppl_2, 1 April 2017, Pages ii151–ii158 available online at https://doi.org/10.1093/ndt/gfw398is

For additional information about this publication click this link. http://qmro.qmul.ac.uk/xmlui/handle/123456789/37965

Information about this research object was correct at the time of download; we occasionally make corrections to records, please therefore check the published record when citing. For more information contact scholarlycommunications@qmul.ac.uk
Exome sequencing and rare variant analysis reveals multiple filaggrin mutations in Bangladeshi atopic eczema families and novel risk genes

Manuela Pigors¹, John E. A. Common², Xuan Fei Colin C. Wong², Sajid Malik³, Claire A. Scott¹, Niloo Far Tabarra¹, Herty Liany⁴, Jianjun Liu⁴, Vachiranee Limviphuvadh⁵, Sebastian Maurer-Stroh⁵, Mark BY Tang⁶, Nicholas Lench⁷, David J. Margolis⁸, David A. van Heel¹, Charles A. Mein⁹, Natalija Novak¹⁰, Hansjörg Baurecht¹¹, Stephan Weidinger¹¹, W.H. Irwin McLean¹², Alan D. Irvine¹³, Edel A. O’Toole¹, Michael A. Simpson¹⁴,¹⁵, David P. Kelsell¹,¹⁵

AFFILIATIONS:

¹Blizard Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
²Institute of Medical Biology, ASTAR, Singapore, Singapore
³Department of Animal Sciences, Faculty of Biological Sciences, Quaid-i-Azam University, Islamabad, Pakistan
⁴Genome Institute of Singapore, A*STAR, Singapore, Singapore
⁵Bioinformatics Institute, A*STAR, Singapore, Singapore
⁶National Skin Centre, Singapore, Singapore
⁷Congenica Limited, Genome Campus, Hinxton, UK
⁸Department of Biostatistics and Epidemiology and Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
⁹The Genome Center, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
¹⁰Department of Dermatology and Allergy, University Hospital Bonn, Bonn, Germany
11Department of Dermatology, Allergology and Venereology, University Hospital Schleswig-Holstein, Kiel, Germany
12Dermatology and Genetic Medicine, University of Dundee, Dundee, UK
13National Children's Research Centre, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Department of Paediatric Dermatology, Our Lady's Children's Hospital Crumlin, Dublin, Ireland; Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland.
14Division of Genetics and Molecular Medicine, King's College London, Guy's Hospital, Great Maze Pond, London, UK
15These authors contributed equally to this work and are joint senior authors

CORRESPONDING AUTHOR:
David P. Kelsell, PhD
Centre for Cell Biology & Cutaneous Research
Blizard Institute
Barts and the London School of Medicine and Dentistry
Queen Mary University of London
4 Newark Street
London E1 2AT
United Kingdom
d.p.kelsell@qmul.ac.uk
Atopic eczema (AE) is a heterogeneous chronic inflammatory skin condition that affects approximately 15-20% of children worldwide (Nutten, 2015). The prevalence varies widely among different countries, between rural and urban areas within a single country and particular Asian skin types are more sensitive to urban environments (Krutmann et al., 2014, Ben-Gashir et al., 2004, Nutten, 2015, Odhiambo et al., 2009). In this study, we analyzed the genetic architecture of AE patients from the South Asian Bangladeshi community in East London (UK) using Whole Exome Sequencing (WES) combined with rare variant enrichment analysis. A total of 70 Bangladeshi Sylheti families each with at least two affected siblings presenting with severe AE (determined by National Institute for Health and Care Excellence (NICE) guidelines) were recruited via the pediatric dermatology clinic at the Royal London Hospital, London (UK). The majority of the affected individuals were born in the UK and also presented with very high IgE levels and other atopic phenotypes, such as food allergy, asthma and hay fever.

Genomic DNA was extracted from EDTA-peripheral blood samples from family members after written informed consent and in adherence with the Declaration of Helsinki Principles and approval from the East London and City Health Authority. WES was performed in 43 probands of 42 Bangladeshi families and an enrichment analysis was performed towards identifying possible AE associated rare coding gene variants. Exome capture and enrichment was performed using various versions of the Agilent capture platform. The subsequent DNA library was sequenced with 100 bp paired-end reads on the HiSeq 2000 platform (Illumina). Resulting sequence data were aligned to the hg19 human reference genome using the Novoalign alignment tool (Novocraft Technologies Sdn Bhd). Sequence variants were called with SAMtools and annotated with ANNOVAR (Wang et al., 2010). Variants were filtered for novelty by comparison to ExAC, in-house exomes, dbSNP137 and
1000 genomes. The association analysis is based on the hypothesis, that multiple rare variants can contribute to the genetic susceptibility to common diseases (Schork et al., 2009). We sought to establish the presence of an excess of rare dominant (<1%) and low frequency recessive (<5%) missense, frameshift, and nonsense variants between 43 probands and 232 ethnically matched unrelated control samples, association was assessed using a simple Fisher’s exact test.

This analysis revealed that filaggrin (FLG) harbored the highest number of enriched dominant (Odds ratio = 12.1, $P < 0.0001$) and recessive loss-of-function, i.e. nonsense and frameshift mutations (Odds ratio = 43.4, $P < 0.0001$) (Table 1). FLG missense variants were not enriched in the Bangladeshi probands. In total, 13 loss-of-function FLG variants, of which five were unreported variants, were identified in 21 of the 43 Bangladeshi probands using WES (Figure 1a, Supplementary Table S1). Moreover, the presence of numerous FLG loss-of-function mutations among the Bangladeshi probands, prompted us to sequence further affected family members (n=42) and probands (n=34) from 28 additional Bangladeshi families using a targeted array-based resequencing assay for FLG (Wong et al., 2017). All FLG loss-of-function variants were validated using Sanger sequencing and tested for segregation in all available family members. This revealed five additional variants in 33 probands, of which three were previously unreported mutations: c.2767insT (p.S923Ffs*2), c.4630delA (p.T1545Qfs*163), and c.7055C>G (p.S2352*) (Figure 1a, Supplementary Table S1). Furthermore, these genetic data revealed intrafamilial heterogeneity with multiple FLG variants often segregating within the Bangladeshi AE families (Figure 1b, Supplementary Table S1).

In addition, this rare variant association testing led to the identification of a potential burden of risk variants in as yet unreported AE associated gene loci, including ADCY10, CUX2, MAST2, MCM10, MTF1, ORM2, PANX3, PHLDB1, SCAND3, TCHHL1 (Table 1, Supplementary Table S1).
**Supplementary Table S2.** The rare sequence variation of top 10 candidate genes in exome data from other AE cohorts with European, African-American, and Singapore Chinese ancestry was also analysed using allele frequencies of population-specific control exome data from the ExAC genome browser (accessed September 13-17, 2017; http://exac.broadinstitute.org/) (Figure 1c, Supplementary Tables S3 and S4). Allele frequencies were analyzed descriptively.

The comparison of the rare risk variants in AE compared to the ExAC data showed that the Bangladeshi AE-associated risk loci were, in part, also identified in the additional populations, with some AE risk variants shared between populations, e.g. ADCY10, CUX2, MAST2, ORM2, while others maybe ethnicity-specific, e.g. MTF1, PANX3, TCHHL1 (Figure 1c, Supplementary Tables S3 and S4). Preliminary data showed that MTF1, ORM2 and TCHHL1 also appear to be replicated in Irish AE exomes (Supplementary Tables S3 and S4).

This rare variant enrichment strategy demonstrated that FLG represents the major AE risk gene in the Bangladeshi population with approximately 50% of AE affected individuals carrying one or more FLG loss-of-function variant. In contrast to FLG, whose role in the epidermis has been characterized in much detail, the precise function of the proposed novel AE gene variants is, at present, not defined (Supplementary Table S2). We postulate that rare coding variants particularly MTF1 (a metal-regulatory transcription factor that regulates expression of, for example, cadmium and zinc) (Gunther et al., 2012, Kimura and Kambe, 2016), and ORM2 (a regulator of sphingolipid homeostasis) (Gururaj et al., 2013) could play a significant role in AE disease expression, regulation of immune responses, and/or environmental sensing.

This study revealed novel insights into the genetic landscape of AE and adds to our multiethnic understanding of AE. Rare putative loss of function alleles in FLG was identified
as a major component of disease susceptibility in the Bangladeshi AE cohort, however, the burden analysis also identified a series of putative novel AE risk loci. Whilst the scope of replication was limited, additional evidence for the role of some of these genes in AE was also observed in three cohorts of individuals with AE from distinct ethnic ancestries.

CONFLICT OF INTEREST:
None.

ACKNOWLEDGEMENTS
We would like to thank the families for their participation in this study. We acknowledge the contributions of Jean Robinson and Dr David Paige for their assistance in identifying the families. M.P was supported by a Fellowship from the German Research Foundation (DFG). This work received infrastructure support through the DFG Cluster of Excellence “Inflammation at Interfaces” (grants EXC306 and EXC306/2), and was supported by grants (WE2678/6-1, WE2678/6-2, WE2678/9) from the DFG and the e:Med sysINFLAME grant no. 01ZX1306A from the German Federal Ministry of Education and Research (BMBF). J.E.A.C. and X.F.C.C.W. are funded by A*STAR SPF funding for translational skin research and genetic orphan diseases.
REFERENCES


Table 1: Exome sequencing and subsequent enrichment of rare variants led to the identification of new risk genes linked to atopic eczema

<table>
<thead>
<tr>
<th>GENE/GENE NAME</th>
<th>MUTATION TYPE</th>
<th>CHROMO-SOME</th>
<th>ODDS RATIO</th>
<th>P-VALUE</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLG/Filaggrin</td>
<td>recessive frameshift or nonsense</td>
<td>1 (152276443-152286591)</td>
<td>43.4</td>
<td>&lt; 0.0001</td>
</tr>
<tr>
<td></td>
<td>dominant frameshift or nonsense</td>
<td>12.1</td>
<td></td>
<td></td>
</tr>
<tr>
<td>SCAND3 (ZBED9)/SCAN Domain Containing Protein 3 (Zinc Finger BED-Type Containing 9)</td>
<td>dominant missense</td>
<td>6 (28542927-28554107)</td>
<td>30.8</td>
<td>0.0002</td>
</tr>
<tr>
<td>TCHHL1/Trichohyalin Like 1</td>
<td>recessive missense</td>
<td>1 (152057583-152060564)</td>
<td>25.0</td>
<td>0.0008</td>
</tr>
<tr>
<td>ADCY10/Adenylate Cyclase 10</td>
<td>dominant frameshift or nonsense</td>
<td>1 (167778964-167871251)</td>
<td>19.5</td>
<td>0.0041</td>
</tr>
<tr>
<td>MTF1/Metastasis Associated 1</td>
<td>dominant missense</td>
<td>1 (38280953-38323065)</td>
<td>7.6</td>
<td>0.0030</td>
</tr>
<tr>
<td>MCM10/Minichromosome Maintenance 10 Replication Initiation Factor</td>
<td>dominant missense</td>
<td>10 (13213067-13251266)</td>
<td>6.2</td>
<td>0.0004</td>
</tr>
<tr>
<td>ORM2/Orosomucoid 2</td>
<td>dominant missense</td>
<td>9 (117092297-117094168)</td>
<td>6.1</td>
<td>0.0015</td>
</tr>
<tr>
<td>CUX2/Cut Like Homeobox 2</td>
<td>dominant missense</td>
<td>12 (111729278-111786109)</td>
<td>5.3</td>
<td>0.0026</td>
</tr>
<tr>
<td>MAST2/Microtubule Associated Serine/Threonine Kinase 2</td>
<td>dominant missense</td>
<td>1 (46463419-46501578)</td>
<td>4.9</td>
<td>0.0021</td>
</tr>
<tr>
<td>PHLD1/</td>
<td>recessive missense</td>
<td>11</td>
<td>4.5</td>
<td>0.0082</td>
</tr>
<tr>
<td>Pleckstrin Homology Like Domain Family B Member 1</td>
<td>(118485376-118520801)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td><strong>PANX3</strong>/Pannexin 3</td>
<td>dominant missense</td>
<td>11</td>
<td>infinity</td>
<td></td>
</tr>
<tr>
<td></td>
<td>(124487339-124489689)</td>
<td></td>
<td>0.0002</td>
<td></td>
</tr>
</tbody>
</table>
Figure 1: Filaggrin (FLG) risk variants identified in the Bangladeshi atopic eczema (AE) cohort and novel risk genes.

(a) Schematic representation of FLG showing all loss-of-function variants identified in this study. (Red arrows indicate previously unreported variants, variants shown black and gray were identified using whole exome sequencing or targeted re-sequencing, respectively) (b)
Exome and targeted resequencing demonstrated an intrafamilial heterogeneity of FLG risk variants in the Bangladeshi AE cohort, segregating, in part, within families. Of note, the parents and the oldest sibling (all unaffected) of both families were born in Bangladesh. All other siblings were born in the UK. (Black symbols indicate affected individuals, gray circle indicates a previously affected daughter, white symbols represent unaffected individuals) 

Heat Maps showing the number of rare variants identified in the different AE cohorts from this study. Data are based on allele frequencies from ethnically-matching subpopulations obtained from the genomic database ExAC. Recessive and dominant variants were considered rare if they had an allele frequency <0.05 and <0.01, respectively. Filaggrin (FLG) loss-of-function variants were excluded in the African-American cohort as described previously (Margolis et al., 2014).